fasudil has been researched along with Fibrosarcoma in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effects of fasudil, a specific ROCK inhibitor, on BRAK secretion and tumor progression in mesenchymal fibrosarcoma cells (MC57)." | 7.78 | Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK. ( Hata, R; Ikoma, T; Izukuri, K; Kato, Y; Kubota, E; Lee, MC; Maehata, Y; Miyamoto, C; Ozawa, S, 2012) |
| " We investigated the effects of fasudil, a specific ROCK inhibitor, on BRAK secretion and tumor progression in mesenchymal fibrosarcoma cells (MC57)." | 3.78 | Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK. ( Hata, R; Ikoma, T; Izukuri, K; Kato, Y; Kubota, E; Lee, MC; Maehata, Y; Miyamoto, C; Ozawa, S, 2012) |
| "Fasudil has been approved for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms." | 1.33 | The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. ( Alicke, B; Biroc, SL; Dinter, H; Kamata, Y; Li, WW; Ohashi, Y; Okada, T; Pagila, R; Xuan, JA; Ying, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, N | 1 |
| Takeda, K | 1 |
| Imai, M | 1 |
| Miyamoto, C | 1 |
| Maehata, Y | 1 |
| Ozawa, S | 1 |
| Ikoma, T | 1 |
| Kubota, E | 1 |
| Izukuri, K | 1 |
| Kato, Y | 1 |
| Hata, R | 1 |
| Lee, MC | 1 |
| Ying, H | 1 |
| Biroc, SL | 1 |
| Li, WW | 1 |
| Alicke, B | 1 |
| Xuan, JA | 1 |
| Pagila, R | 1 |
| Ohashi, Y | 1 |
| Okada, T | 1 |
| Kamata, Y | 1 |
| Dinter, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for fasudil and Fibrosarcoma
| Article | Year |
|---|---|
Inhibitory effects of p-dodecylaminophenol on the invasiveness of human fibrosarcoma cell line HT1080.
Topics: Aminophenols; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fibrosarcoma; | 2013 |
Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cel | 2012 |
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Breast Neoplasms; Cell Adhesion; Cell Growth | 2006 |